These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 15555076)
1. Susceptibility of different leukocyte cell types to Vaccinia virus infection. Sánchez-Puig JM; Sánchez L; Roy G; Blasco R Virol J; 2004 Nov; 1():10. PubMed ID: 15555076 [TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage. Yu Q; Jones B; Hu N; Chang H; Ahmad S; Liu J; Parrington M; Ostrowski M Vaccine; 2006 Sep; 24(40-41):6376-91. PubMed ID: 16859816 [TBL] [Abstract][Full Text] [Related]
3. Poxvirus tropism for primary human leukocytes and hematopoietic cells. Yu Q; Hu N; Ostrowski M Methods Mol Biol; 2009; 515():309-28. PubMed ID: 19378122 [TBL] [Abstract][Full Text] [Related]
4. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox. Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492 [TBL] [Abstract][Full Text] [Related]
5. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917 [TBL] [Abstract][Full Text] [Related]
6. Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity. Kastenmuller W; Drexler I; Ludwig H; Erfle V; Peschel C; Bernhard H; Sutter G Virology; 2006 Jul; 350(2):276-88. PubMed ID: 16595141 [TBL] [Abstract][Full Text] [Related]
7. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983 [TBL] [Abstract][Full Text] [Related]
8. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252 [TBL] [Abstract][Full Text] [Related]
10. A rapid, high-throughput vaccinia virus neutralization assay for testing smallpox vaccine efficacy based on detection of green fluorescent protein. Johnson MC; Damon IK; Karem KL J Virol Methods; 2008 Jun; 150(1-2):14-20. PubMed ID: 18387679 [TBL] [Abstract][Full Text] [Related]
11. Identification of vaccinia CD8+ T-cell epitopes conserved among vaccinia and variola viruses restricted by common MHC class I molecules, HLA-A2 or HLA-B7. Terajima M; Cruz J; Leporati AM; Demkowicz WE; Kennedy JS; Ennis FA Hum Immunol; 2006 Jul; 67(7):512-20. PubMed ID: 16829305 [TBL] [Abstract][Full Text] [Related]
12. Vaccination with a Modified Vaccinia Virus Ankara-based vaccine protects mice from allergic sensitization. Albrecht M; Suezer Y; Staib C; Sutter G; Vieths S; Reese G J Gene Med; 2008 Dec; 10(12):1324-33. PubMed ID: 18816482 [TBL] [Abstract][Full Text] [Related]
13. Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection. Di Lullo G; Soprana E; Panigada M; Palini A; Erfle V; Staib C; Sutter G; Siccardi AG J Virol Methods; 2009 Mar; 156(1-2):37-43. PubMed ID: 19038289 [TBL] [Abstract][Full Text] [Related]
14. T-bet is required for protection against vaccinia virus infection. Matsui M; Moriya O; Yoshimoto T; Akatsuka T J Virol; 2005 Oct; 79(20):12798-806. PubMed ID: 16188982 [TBL] [Abstract][Full Text] [Related]
15. Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model. El-Gogo S; Staib C; Meyr M; Erfle V; Sutter G; Adler H Vaccine; 2007 May; 25(20):3934-45. PubMed ID: 17433507 [TBL] [Abstract][Full Text] [Related]
16. Extracellular vesicles containing virus-encoded membrane proteins are a byproduct of infection with modified vaccinia virus Ankara. Spehner D; Drillien R Virus Res; 2008 Oct; 137(1):129-36. PubMed ID: 18662728 [TBL] [Abstract][Full Text] [Related]
17. HLA-A2-restricted human CD8(+) cytotoxic T lymphocyte responses to a novel epitope in vaccinia virus that is conserved among orthopox viruses. Dong Y; Denny TN J Infect Dis; 2006 Jul; 194(2):168-75. PubMed ID: 16779722 [TBL] [Abstract][Full Text] [Related]
18. [Construction and the immunogenicity of the recombinant Modified Vaccinia Virus Ankala co-expressing ORF4, ORF5 and ORF6 genes of porcine reproductive and Respiratory Syndrome Virus NJ-a strain]. Zheng QS; Bi ZX; Li P; Chen DS; Chen PY Wei Sheng Wu Xue Bao; 2007 Apr; 47(2):345-9. PubMed ID: 17552247 [TBL] [Abstract][Full Text] [Related]
19. Origin-independent plasmid replication occurs in vaccinia virus cytoplasmic factories and requires all five known poxvirus replication factors. De Silva FS; Moss B Virol J; 2005 Mar; 2():23. PubMed ID: 15784143 [TBL] [Abstract][Full Text] [Related]
20. Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules. Tsang KY; Palena C; Yokokawa J; Arlen PM; Gulley JL; Mazzara GP; Gritz L; Yafal AG; Ogueta S; Greenhalgh P; Manson K; Panicali D; Schlom J Clin Cancer Res; 2005 Feb; 11(4):1597-607. PubMed ID: 15746065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]